Oliverio Giovanni William, Inferrera Leandro, Postorino Elisa I, Palino Paola, Aragona Pasquale
Department of Biomedical Sciences, Ophthalmology Clinic, University of Messina, Messina, Italy.
Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
Eur J Ophthalmol. 2025 May;35(3):878-883. doi: 10.1177/11206721241293175. Epub 2024 Oct 21.
PurposeTo evaluate the safety and efficacy of netilmicin/dexamethasone combination in the treatment of meibomian gland dysfunction (MGD)-associated posterior blepharitis.MethodsIn this prospective and controlled study were enrolled 40 patients with MGD and symptoms of dry eye disease. Two groups were established: 20 patients (group 1) received netilmicin 3 mg/ml and dexamethasone 1 mg/ml eye gel, whereas in group 2 (20 patients) received vehicle for 15 days. Patients were evaluated at baseline, 15 and 45 days, including SANDE and VARS questionnaire, non-invasive tear film breakup time (NIBUT), tear meniscus height (TMH), ocular redness and meibography score. Moreover, fluorescein tear-film breakup time (TBUT), fluorescein ocular surface staining, lid margin evaluation including hyperemia, edema and meibum expressibility and quality examinations were carried out. Furthermore, intraocular pressure (IOP) and best-corrected visual acuity (BCVA) were considered as safety parameters.ResultsIn group 1, at 15 and 45 days there were statistically significant changes in VARS and SANDE score (p < 0.0001) as well as lid margin parameters, TBUT and fluorescein ocular surface staining (p < 0.0001). Comparing the two groups, a significant improvement of SANDE score was observed at 15 days in group 1 as well as lid margin parameters, TBUT and fluorescein ocular surface staining at 15 and 45 days (all p < 0.0001).ConclusionNetilmicin/dexamethasone combination is effective and safe to treat MGD-associated posterior blepharitis improving both symptoms and ocular surface signs.
目的
评估奈替米星/地塞米松联合用药治疗睑板腺功能障碍(MGD)相关睑后炎的安全性和有效性。
方法
本前瞻性对照研究纳入了40例患有MGD且有干眼症状的患者。分为两组:20例患者(第1组)接受3 mg/ml奈替米星和1 mg/ml地塞米松眼凝胶,而第2组(20例患者)接受赋形剂,为期15天。在基线、第15天和第45天对患者进行评估,包括SANDE和VARS问卷、非侵入性泪膜破裂时间(NIBUT)、泪河高度(TMH)、眼发红和睑板腺造影评分。此外,还进行了荧光素泪膜破裂时间(TBUT)、荧光素眼表染色、睑缘评估,包括充血、水肿和睑脂排出能力及质量检查。此外,眼压(IOP)和最佳矫正视力(BCVA)被视为安全性参数。
结果
在第1组中,第15天和第45天时,VARS和SANDE评分(p < 0.0001)以及睑缘参数、TBUT和荧光素眼表染色(p < 0.0001)有统计学显著变化。比较两组,第1组在第15天时SANDE评分有显著改善,在第15天和第45天时睑缘参数、TBUT和荧光素眼表染色也有显著改善(所有p < 0.0001)。
结论
奈替米星/地塞米松联合用药治疗MGD相关睑后炎有效且安全,可改善症状和眼表体征。